Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8201	Companies
109005	Keywords
51275	Articles
60079	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 10/16/2024 at 06:55, 18 days 6 hours ago

La percée de Formycon dans le développement de produits biosimilaires

Formycon AG Essais Cliniques Keytruda® Biosimilaire FYB206 Similitude Analytique
BRIEF

published on 10/16/2024 at 06:55, 18 days 6 hours ago

Formycon's Breakthrough in Biosimilar Development

Clinical Trials Formycon AG Biosimilar FYB206 Analytical Similarity Keytruda®
PRESS RELEASE

published on 10/16/2024 at 06:50, 18 days 6 hours ago

Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
Formycon publishes study results in peer-reviewed journal analyzing biosimilar candidate FYB206 and Keytruda, showing high similarity in structure and function. Results support ongoing clinical trials

Clinical Trials Biosimilar Formycon FYB206 Keytruda
BRIEF

published on 10/01/2024 at 17:11, 1 month 1 day ago

Le biosimilaire FYB202 de Formycon AG approuvé pour les marchés de l'UE et des États-Unis

Formycon AG Approbation De La FDA Entrée Sur Le Marché Biosimilaire Analyse D'investissement
BRIEF

published on 10/01/2024 at 17:11, 1 month 1 day ago

Formycon AG's FYB202 Biosimilar Approved for EU and US Markets

FDA Approval Formycon AG Market Entry Biosimilar Investment Analysis
PRESS RELEASE

published on 10/01/2024 at 17:06, 1 month 1 day ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects

Investment Recommendation Formycon AG First Berlin Equity Research GmbH FYB202 Approval Biosimilar Market
BRIEF

published on 09/30/2024 at 07:35, 1 month 3 days ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
BRIEF

published on 09/30/2024 at 07:35, 1 month 3 days ago

Formycon et Fresenius Kabi reçoivent l'approbation de la FDA pour le biosimilaire Otulfi

Approbation De La FDA Formycon Fresenius Kabi Biosimilaire Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 month 3 days ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 month 5 days ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®

Accesswire

Published on 11/03/2024 at 00:45, 12 hours 43 minutes ago

Holtway Global Hedge Expands into Europe, Providing Exclusive Pre-IPO and IPO Access to Companies Led by Visionary Founders like Elon Musk and Sam Altman
Published on 11/02/2024 at 19:15, 18 hours 13 minutes ago

Hank Payments Announces Closing of Financing and Settlements
Published on 11/02/2024 at 16:10, 21 hours 18 minutes ago

Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/02/2024 at 14:30, 22 hours 58 minutes ago

Spa Sciences Health Introduces Revolutionary Nasal Irrigation System at CVS
Published on 11/02/2024 at 00:48, 1 day 12 hours ago

OneSoft Solutions Inc. Announces the Completion of Its Acquisition by Irth Solutions LLC, a Blackstone Portfolio Company

View all ACCESSWIRE

EQS Group

Published on 11/01/2024 at 21:31, 1 day 15 hours ago

Original-Research: Telefonica Deutschland Holding AG (von First Berlin Equity Research GmbH): Buy
Published on 11/01/2024 at 18:18, 1 day 19 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/01/2024 at 17:47, 1 day 19 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/01/2024 at 17:10, 1 day 20 hours ago

EQS-Adhoc: fox e-mobility AG: provisional debt restructuring moratorium of Fox Automotive Switzerland AG
Published on 11/01/2024 at 16:00, 1 day 21 hours ago

Total Voting Rights

Les Echos

Published on 10/31/2024 at 20:26, 2 days 17 hours ago

I.CERAM - Résultat du 1er semestre 2024
Published on 10/31/2024 at 18:19, 2 days 19 hours ago

Déclaration hebdomadaire d'opérations effectuées du 28 au 31 octobre 2024
Published on 10/31/2024 at 18:19, 2 days 19 hours ago

Disclosure of transactions in own shares on October 28 to October 31, 2024
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION : CHIFFRE D’AFFAIRES TROISIEME TRIMESTRE 2024 : +3%
Published on 10/31/2024 at 18:00, 2 days 19 hours ago

GUILLEMOT CORPORATION: THIRD QUARTER 2024 TURNOVER UP 3%

View all LES ECHOS COMFI WIRE